The SAS subsidiary's new enhancement leverages vastly expanded consumer rate shopping data, offering hoteliers granular visibility across room types and distribution channels to refine pricing strategies.
The Centers for Medicare & Medicaid Services (CMS) has unveiled a proposed payment update for Medicare Advantage plans that falls below industry expectations, coupled with stricter risk-adjustment regulations. This dual challenge pressures insurers like Oscar Health (NYSE: OSCR), whose tech-driven model is now under the microscope as profitability margins face a squeeze.
A fatal grain bin accident in rural Illinois has left one man dead and another seriously injured after both became trapped in soybeans, highlighting the persistent dangers of agricultural confined spaces.
Sean Grayson receives maximum sentence for second-degree murder in the 2024 killing of Sonya Massey, an unarmed Black mother who had called 911 for help.
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
The Horatio Alger Award bestowed upon ResMed founder Dr. Peter Farrell underscores the company's decades-long leadership in sleep and respiratory care, bringing its financial performance and competitive strategy into sharper focus for investors.
Brokerage firm CLSA initiates coverage on Atour Lifestyle Holdings with an 'Outperform' rating and a $49 price target, highlighting its unique brand ecosystem and asset-light model as key differentiators in a competitive market.
RBC Capital has reaffirmed its confidence in Ascendis Pharma, raising its price target following the company's ambitious 2026 strategic goals, which hinge on sustained momentum for its lead therapy and significant long-term revenue targets.
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
Sciwind Biosciences secures Chinese approval for its GLP-1 agonist Xianyida, entering a crowded but high-stakes diabetes treatment market dominated by global giants, as the country grapples with the world's largest diabetic population.
MTY Food Group's recent 12% dividend hike and recognition as a top pick have reignited investor interest. However, a closer look reveals a complex valuation story, with a premium P/E ratio contrasting sharply with discounted cash flow models and recent profit margin pressures.
Amidst a backdrop of geopolitical tensions and market volatility, a closer look reveals resilient European companies whose current share prices may not reflect their underlying strength and future growth prospects.
ResMed Inc. reports an 11% revenue surge for its second fiscal quarter, driven by robust mask sales and strategic acquisitions, while navigating competitive pressures and capitalizing on emerging healthcare trends.
The medical technology giant reports double-digit organic sales growth for the fourth consecutive year, driven by its Mako robotic system and strategic leadership shifts, while navigating tariffs and a shifting competitive landscape.
Becton Dickinson announces a major spin-off of its Biosciences unit to combine with Waters Corporation, alongside a successful pilot to recycle polystyrene labware, signaling a dual push towards portfolio focus and sustainability.
Proposed flat payment rates for 2027 by CMS intensify margin pressures on Medicare Advantage insurers like Clover Health, raising investor concerns about cost management and growth prospects in a tightening regulatory landscape.
A disappointing full-year EBITDA performance from its crucial Macau operations triggered a sharp sell-off in Las Vegas Sands stock, underscoring the lingering challenges facing the gaming giant in the wake of China's regulatory crackdown.
MGM Resorts International is powering its Las Vegas Strip operations with a major new solar and battery storage deal. This strategic shift toward renewables comes as the company's stock shows mixed signals, trading below some fair value estimates yet at a high earnings multiple, leaving investors to weigh long-term sustainability against immediate financial metrics.
Cardinal Health (CAH) stock has drawn renewed investor interest following robust financial results, with revenue topping $234 billion and net income near $1.6 billion. The healthcare distributor's shares have rallied over 66% in the past year, though its premium valuation compared to peers is sparking debate among analysts.
Once the engine of Venezuela's wealth, the communities around Lake Maracaibo now stand as decaying monuments to the nation's oil collapse. As a controversial U.S. plan promises a $100 billion investment, residents of the ghostly 'oil camps' are caught between desperate hope and deep-seated skepticism.
